Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global market for next-generation antibody therapeutics is on the brink of exponential growth, driven by their high efficiency and safety. Advancements in monoclonal antibody technology are contributing to the market's expansion, with biosimilar antibody products gaining traction. The ongoing investments in the healthcare sector, especially during the COVID-19 pandemic, are expected to propel the market in the coming years. Fairfield Market Research predicts robust revenue growth over the next five years, with North America, led by the developing market in the US, and the Asia Pacific, driven by booming economies like China and India, playing significant roles in the market's expansion.

Key Market Dynamics

The growth of the next-generation antibody therapeutics market is influenced by several key factors:

Advancements in Monoclonal Antibodies: The initial success of monoclonal antibodies has paved the way for the development of next-generation antibody therapeutics. Researchers are continually striving to create improved, more efficient, and safer antibody therapeutics, addressing the needs of chronic disease treatments.
Prevalence of Chronic Disorders: The rising incidence of chronic diseases is driving demand for more effective treatments. Next-generation antibody therapeutics offer enhanced features that can address the limitations of monoclonal antibodies.
Government Funding: Governments are increasing funding and grants for research in the antibody therapeutics sector, coupled with rising healthcare expenditure in developed and developing countries, contributing to market growth.
Investment by Pharmaceutical Companies: Leading pharmaceutical, biopharmaceutical, and biotechnology firms are investing in the development of next-generation therapeutic antibodies for conditions such as autoimmune diseases, inflammatory disorders, and cancers.

However, challenges such as higher costs and stringent regulatory measures, including lengthy approval procedures, may hinder market growth by 2031.

Segment Analysis

The global next-generation antibody therapeutics market is segmented based on technology and application. The drug-antibody conjugates segment continues to dominate the market, while oncology remains the largest therapeutic application.

Regional Analysis

The global market for next-generation antibody therapeutics is divided into four primary regions: North America, Europe, Asia, and the rest of the world. North America stands out as the largest market, with a substantial value recorded in 2023. By the end of 2031, the North American market is expected to experience significant growth, with a notable Compound Annual Growth Rate (CAGR) and reaching a substantial value.

Key Players Analysis

The global next-generation therapeutic antibodies market includes numerous pharmaceutical, biopharmaceutical, and biotechnology companies. Leading players are actively engaged in R&D and manufacturing. Prominent companies in the market include ImmunoGen, Inc., Bayer AG, Biogen, Xencor, Inc., F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Dyax Corp., Amgen, Inc., and Seattle Genetics, Inc.

1. Executive Summary

1.1. Global Next Generation Antibody Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

3.1. Global Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Oncology
  - 3.1.1.2. Autoimmune/Inflammatory
3.2. Global Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Antibody-drug conjugates (ADCs)
  - 3.2.1.2. Bispecific antibodies
  - 3.2.1.3. Fc engineered antibodies
  - 3.2.1.4. Antibody fragments and antibody-like proteins
  - 3.2.1.5. Biosimilar antibody products
3.3. Global Next Generation Antibody Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

4.1. North America Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Oncology
  - 4.1.1.2. Autoimmune/Inflammatory
4.2. North America Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Antibody-drug conjugates (ADCs)
  - 4.2.1.2. Bispecific antibodies
  - 4.2.1.3. Fc engineered antibodies
  - 4.2.1.4. Antibody fragments and antibody-like proteins
  - 4.2.1.5. Biosimilar antibody products
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Next Generation Antibody Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

5.1. Europe Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Oncology
  - 5.1.1.2. Autoimmune/Inflammatory
5.2. Europe Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Antibody-drug conjugates (ADCs)
  - 5.2.1.2. Bispecific antibodies
  - 5.2.1.3. Fc engineered antibodies
  - 5.2.1.4. Antibody fragments and antibody-like proteins
  - 5.2.1.5. Biosimilar antibody products
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Next Generation Antibody Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

6.1. Asia Pacific Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Oncology
  - 6.1.1.2. Autoimmune/Inflammatory
6.2. Asia Pacific Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Antibody-drug conjugates (ADCs)
  - 6.2.1.2. Bispecific antibodies
  - 6.2.1.3. Fc engineered antibodies
  - 6.2.1.4. Antibody fragments and antibody-like proteins
  - 6.2.1.5. Biosimilar antibody products
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Next Generation Antibody Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

7.1. Latin America Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Oncology
  - 7.1.1.2. Autoimmune/Inflammatory
7.2. Latin America Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Antibody-drug conjugates (ADCs)
  - 7.2.1.2. Bispecific antibodies
  - 7.2.1.3. Fc engineered antibodies
  - 7.2.1.4. Antibody fragments and antibody-like proteins
  - 7.2.1.5. Biosimilar antibody products
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Next Generation Antibody Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Next Generation Antibody Therapeutics Market Outlook, 2018 - 2031

8.1. Middle East & Africa Next Generation Antibody Therapeutics Market Outlook, by Therapeutic Area, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Oncology
  - 8.1.1.2. Autoimmune/Inflammatory
8.2. Middle East & Africa Next Generation Antibody Therapeutics Market Outlook, by Technology, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Antibody-drug conjugates (ADCs)
  - 8.2.1.2. Bispecific antibodies
  - 8.2.1.3. Fc engineered antibodies
  - 8.2.1.4. Antibody fragments and antibody-like proteins
  - 8.2.1.5. Biosimilar antibody products
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Next Generation Antibody Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Next Generation Antibody Therapeutics Market by Therapeutic Area, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Next Generation Antibody Therapeutics Market by Technology, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Therapeutic Area vs by Technology Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. F. Hoffmann-La Roche Ltd
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Kyowa Hakko Kirin Co., Ltd.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Seattle Genetics, Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. ImmunoGen, Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Bristol-Myers Squibb Company
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Pfizer, Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Amgen, Inc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Biogen
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Bayer AG
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Xencor, Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Takeda Pharmaceuticals Company Limited
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. AstraZeneca
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Dyax Corp.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations